DURHAM, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, has been granted the U.S. Food and Drug Administration's (FDA's) Regenerative Medicine Advanced Therapy (RMAT) designation for patients with advanced peripheral artery disease (PAD). This RMAT designation is granted at the same time as FDA cleared a new Investigational New Drug (IND) application for ...

– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte's stem cell-derived islets observed to restore normal blood glucose in diabetic mice – – Non-human primate models of BVP implantation showed islet survival and continued insulin production – DURHAM, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinicalstage biotechnology platform company developing universally implantable, bioengineered human tissues at com ...

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Humacyte, Inc. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Heading into today, shares of the company had lost 27.32% over the past month, lagging the Medical sector's gain of 0.44% and the S&P 500's gain of 3.15% in that time. Our research reveals that these estimate alterations are ...

– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte's HAV – – BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinical trial results and real-world use treating wartime trauma injuries in Ukraine – DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinicalstage biotechnology platform company developing universally implantable, Human Acell ...

This week in Cheap Seats: Stocks Under $20 segment, we're taking a look at two stocks that are soaring today: Humacyte Inc (NYSE:HUMA) and American Semiconductor Corp (NASDAQ:AMSC). Humacyte today announced that it would take part in the Jefferies Global Healthcare Conference. At last glance, HUMA was up 20.5% at $9.29, on track for its best day since August 2023 and trading at its highest levels since December 2021. Since the start of the year, the equity is up roughly 230%. AMSC is up 14.6% at $18.10, ear ...

While Nancy Pelosi often dominates discussions on insider trades in the US, the year 2024 has seen a shift in focus to her Republican counterpart, Tommy Tuberville. His series of trades, particularly notable for their insider nature, have sparked significant interest. One of the most talked-about trades is the acquisition of Humacyte (NASDAQ: HUMA) stock in three separate purchases worth approximately $80,000 on March 21. HUMA shares have surged by 96% in just two months since the purchase, almost doubling ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ ...

DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, Dale Sander, Chief Financial Officer, and B.J. Scheessele, Chief Commercial Officer, will represent Humacyte at the following conferences in May. H.C. Wainwright BioConnect Investor Conference at NASDAQ F ...

Humacyte, Inc. (NASDAQ:HUMA) Q1 2024 Earnings Conference Call May 10, 2024 8:00 AM ET Conference Call Participants Good morning, ladies and gentlemen, and welcome to the Humacyte First Quarter 2024 Results Conference Call. Currently all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. Thank you, operator. Before we proceed with the call, I would like to remind everyone ...

Exhibit 99.1 -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43 million in net proceeds from public offering of common stock- -Conference call and live webcast at 8:00 a.m. ET today- First Quarter 2024 and Recent Corporate Highlights Humacyte First Quarter 2024 Financial Results and Business Update HAV in Vascular Trauma -Biologics License Application (BLA) for HAV™ Accepted by FDA- 1 DURHAM, N.C., May 10, 2024 – Humacyte, Inc. (Nasdaq: ...